Press Releases
// May 24, 2023
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth
// May 24, 2023
Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases
// May 15, 2023
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production
// Apr 25, 2023
Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform
// Mar 07, 2023
ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs
// Feb 22, 2023
Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
// Jan 05, 2023
ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference
// Nov 15, 2022
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
// Aug 25, 2022
ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation
// Aug 23, 2022
ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines
// Aug 04, 2022
